LifeSci Pharmaceuticals

LifeSci Pharmaceuticals is a biotechnology company focused on the discovery and development of novel small molecule therapeutics for rare diseases and oncology. Operating as an incubator within the LifeSci Partners ecosystem, the company has advanced several programs, most notably through its subsidiary Attune Pharmaceuticals. Its lead candidate, ATN-249, was an oral plasma kallikrein inhibitor developed for the treatment of hereditary angioedema (HAE) that reached Phase 1 clinical trials. The company's broader research portfolio includes intellectual property for small molecule inhibitors of complement factor D and epigenetic targets such as KDM5B. LifeSci Pharmaceuticals leverages the strategic and financial resources of LifeSci Partners to identify and develop high-potential assets from early discovery through clinical proof-of-concept.